<?xml version="1.0" encoding="UTF-8"?>
<p>NEPA was well tolerated with a comparable adverse event profile to APR/GRAN. The majority of AEs were mild/moderate in intensity, unrelated to study treatment, and typical for a cancer population undergoing chemotherapy. There were no cardiac safety concerns for either treatment.</p>
